Peptide vaccines in cancer — old concept revisited

Takumi Kumai; Hiroya Kobayashi; Yasuaki Harabuchi; Esteban Celis

doi:10.1016/j.coi.2016.11.001

Peptide vaccines in cancer — old concept revisited

Takumi Kumai, Hiroya Kobayashi, Yasuaki Harabuchi, Esteban Celis

Oncology Research

Research output: Contribution to journal › Review article › peer-review

85 Scopus citations

Abstract

Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.

Original language	English (US)
Pages (from-to)	1-7
Number of pages	7
Journal	Current Opinion in Immunology
Volume	45
DOIs	https://doi.org/10.1016/j.coi.2016.11.001
State	Published - Apr 1 2017

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.coi.2016.11.001

Cite this

@article{503c2137876a4154a539200022e9392c,

title = "Peptide vaccines in cancer — old concept revisited",

abstract = "Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.",

author = "Takumi Kumai and Hiroya Kobayashi and Yasuaki Harabuchi and Esteban Celis",

note = "Funding Information: This work was supported by a grant from the National Cancer Institute of the National Institutes of Health, R01CA157303, and by start-up funds from Augusta University Georgia Cancer Center and the Georgia Research Alliance (GRA). Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd",

year = "2017",

month = apr,

day = "1",

doi = "10.1016/j.coi.2016.11.001",

language = "English (US)",

volume = "45",

pages = "1--7",

journal = "Current Opinion in Immunology",

issn = "0952-7915",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Peptide vaccines in cancer — old concept revisited

AU - Kumai, Takumi

AU - Kobayashi, Hiroya

AU - Harabuchi, Yasuaki

AU - Celis, Esteban

N1 - Funding Information: This work was supported by a grant from the National Cancer Institute of the National Institutes of Health, R01CA157303, and by start-up funds from Augusta University Georgia Cancer Center and the Georgia Research Alliance (GRA). Publisher Copyright: © 2016 Elsevier Ltd

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.

AB - Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.

UR - http://www.scopus.com/inward/record.url?scp=85002810614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002810614&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2016.11.001

DO - 10.1016/j.coi.2016.11.001

M3 - Review article

C2 - 27940327

AN - SCOPUS:85002810614

SN - 0952-7915

VL - 45

SP - 1

EP - 7

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

ER -